Sacituzumab govitecan plus pembrolizumab improves survival in advanced triple-negative breast cancerSacituzumab govitecan plus pembrolizumab improves survival in advanced triple-negative breast cancer
1. Among patients with previously untreated programmed death-ligand 1 positive, triple-negative breast cancer, first-line sacituzumab govitecan plus pembrolizumab significantly prolonged progression-free survival compared to chemotherapy plus pembrolizumab. 2. The sacituzumab combination was also associated with longer response duration and fewer treatment discontinuations due to adverse events, despite similar rates of high-grade toxicities. Evidence Rating Level:
The post Sacituzumab govitecan plus pembrolizumab improves survival in advanced triple-negative breast cancer first appeared on 2 Minute Medicine. Source: 2 Minute Medicine
Dual GIP/GLP-1 Drug Linked to Reduced Diabetic Retinopathy IncidenceDual GIP/GLP-1 Drug Linked to Reduced Diabetic Retinopathy Incidence
(MedPage Today) — Use of tirzepatide (Mounjaro, Zepbound) was tied to a reduced incidence of new or progressive diabetic retinopathy and fewer complications in patients with diabetes and overweight/obesity, a retrospective study suggested. In… (MedPage Today) — Use of tirzepatide (Mounjaro, Zepbound) was tied to a reduced incidence of new or progressive diabetic retinopathy Read More
Study raises red flags over long-term effectiveness of popular weight loss drugs like OzempicStudy raises red flags over long-term effectiveness of popular weight loss drugs like Ozempic
Ozempic, Mounjaro, and Zepbound can drive impressive weight loss, but stopping them is often followed by rapid weight regain. Researchers found that people regain weight faster after quitting these drugs than after diet and exercise alone. Improvements in heart health and diabetes risk also tend to reverse within a few years. The results suggest long-term Read More
GLP-1 RAs and Prior Major Adverse Limb Events in Patients With DiabetesGLP-1 RAs and Prior Major Adverse Limb Events in Patients With Diabetes
This cohort study analyzes associations of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) with risk of recurrent major adverse limb events in patients with diabetes. This cohort study analyzes associations of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) with risk of recurrent major adverse limb events in patients with diabetes.
Medicaid Expansion Linked to Lower Mortality in Breast CancerMedicaid Expansion Linked to Lower Mortality in Breast Cancer
(MedPage Today) — Medicaid expansion under the Affordable Care Act (ACA) was associated with lower overall mortality among women with breast cancer, according to a retrospective cohort study.
Among over 1.5 million women ages 40 to 64, Medicaid…
New therapeutic target for breast cancer involves double-stranded RNA-binding proteinsNew therapeutic target for breast cancer involves double-stranded RNA-binding proteins
A Purdue University team has discovered a new therapeutic target for triple-negative breast cancer. The research, led by Kyle Cottrell, an assistant professor of biochemistry, spotlights double-stranded ribonucleic acid (dsRNA)-binding proteins.
Tirzepatide Safety Warning; Nurse Charged Over Fake GLP-1s; Revised Afrezza DosingTirzepatide Safety Warning; Nurse Charged Over Fake GLP-1s; Revised Afrezza Dosing
(MedPage Today) — Tirzepatide (Mounjaro, Zepbound) users should never share KwikPens due to risk for transmission of blood-borne pathogens, the FDA warned in an updated label. GLP-1 medications for weight loss accounted for more than 7% of all… (MedPage Today) — Tirzepatide (Mounjaro, Zepbound) users should never share KwikPens due to risk for transmission Read More
Oral semaglutide reshapes everyday obesity visitsOral semaglutide reshapes everyday obesity visits
1. Oral semaglutide adds a pill-based option for chronic obesity care without changing the core GLP-1 tradeoffs in efficacy and gastrointestinal tolerability. 2. Clinicians will need to help patients understand that daily dosing, titration, and safety monitoring remain essential even when the formulation feels more convenient. The emergence of an oral GLP-1 option for chronic Read More
STAT+: New startup to develop a GLP-1 drug for addictionSTAT+: New startup to develop a GLP-1 drug for addiction
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. A new startup focused on GLP-1 drugs launched today, but unlike the dozens of other GLP-1 companies, this one isn’t studying weight loss. The need-to-know this morning Roche plans to launch Phase Read More
GLP-1 drugs don’t work for everyone. But personalized obesity care in the future mightGLP-1 drugs don’t work for everyone. But personalized obesity care in the future might
As doctors learn why GLP-1s don’t work for about 50% of people, they are also learning more about the complex drivers of obesity. They foresee a future of personalized obesity medicine similar to the way cancer is treated now. (Image credit: Tatsiana Volkava) As doctors learn why GLP-1s don’t work for about 50% of Read More